Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05321420 · ClinicalTrials.gov registry record · Phase 2
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by PureTech.
- Active
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT05321420: Active Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by PureTech.
NCT05321420 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that is active but no longer recruiting, run by PureTech. The registered enrollment target is 240 participants, below the 747-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05321420, a Phase 2 study of Idiopathic Pulmonary Fibrosis, is active but no longer recruiting, sponsored by PureTech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
Primary Outcome
Rate of decline in Forced Vital Capacity (FVC; in mL)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pirfenidone
- DRUG Deupirfenidone
Study Locations (20)
California
- Science 37 - Los Angeles
- NewportNativeMD, Inc. - Newport Beach
- Paradigm Clinical Research Centers, Inc. - Redding
- Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center - Torrance
Florida
- Accel Research Sites Network - DeLand
- Harmony Medical Research Institute, Inc - Hialeah
Georgia
- Piedmont Healthcare, Inc. - Atlanta
- Clinical Research Investments - Decatur
North Carolina
- Pulmonix - Greensboro
- Southeastern Research Center - Winston-Salem
Tennessee
- Clinical Trials Center of Middle Tennessee - Franklin
- Vanderbilt University Medical Center - Nashville
Texas
- Baylor Scott & White Research Institute - Dallas
- Renovatio Clinical - The Woodlands Research Center - The Woodlands
Alabama
- University of Alabama Birmingham - Birmingham
Connecticut
- University of Connecticut Health Center - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2022-07-22 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05321420 still lists
NCT05321420 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 747-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05321420 names 20 study sites across 12 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05321420 about?
NCT05321420 is a clinical study titled "LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)". This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
What is the current status of trial NCT05321420?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2022-07-22. Estimated completion is 2025-12-31.
What conditions does trial NCT05321420 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT05321420?
The interventions under investigation include: Placebo (DRUG), Pirfenidone (DRUG), Deupirfenidone (DRUG).
Who is sponsoring clinical trial NCT05321420?
This trial is sponsored by PureTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05321420 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05321420's enrollment target sits among peer trials
240 14th of 51 higher than 38 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
RECRUITING · Phase 2
-
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI